{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T20:51:57Z","timestamp":1787863917444,"version":"build-2784847793"},"reference-count":34,"publisher":"Society of Nuclear Medicine","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"accepted":{"date-parts":[[2024,8,2]]},"published-print":{"date-parts":[[2024,10]]},"DOI":"10.2967\/jnumed.124.267964","type":"journal-article","created":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T17:00:46Z","timestamp":1726160446000},"page":"1584-1590","source":"Crossref","is-referenced-by-count":9,"title":["Quantitative SPECT\/CT Metrics in Early Prediction of [<sup>177<\/sup>Lu]Lu-DOTATATE Treatment Response in Gastroenteropancreatic Neuroendocrine Tumor Patients"],"prefix":"10.2967","volume":"65","author":[{"given":"Onur","family":"Tuncer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Steinberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Steiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madeleine","family":"Hinojos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie Y.","family":"Rhee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brad","family":"Humphrey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farhad","family":"Jafari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuzan","family":"Cayci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2024,9,12]]},"reference":[{"key":"2024100105350748000_65.10.1584.1","doi-asserted-by":"crossref","first-page":"114","DOI":"10.3390\/ph12030114","article-title":"Lutathera\u00ae: the first FDA- and EMA-approved radiopharmaceutical for peptide receptor radionuclide therapy","volume":"12","author":"Hennrich","year":"2019","journal-title":"Pharmaceuticals (Basel)."},{"key":"2024100105350748000_65.10.1584.2","doi-asserted-by":"publisher","DOI":"10.1089\/cbr.2014.1741"},{"key":"2024100105350748000_65.10.1584.3","doi-asserted-by":"crossref","first-page":"e28970","DOI":"10.1097\/MD.0000000000028970","article-title":"Peptide receptor radionuclide therapy implementation and results in a predominantly gastrointestinal neuroendocrine tumor population: a two-year experience in a nonuniversity setting","volume":"101","author":"Mejia","year":"2022","journal-title":"Medicine (Baltimore)."},{"key":"2024100105350748000_65.10.1584.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607427"},{"key":"2024100105350748000_65.10.1584.5","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00572-6"},{"key":"2024100105350748000_65.10.1584.6","doi-asserted-by":"crossref","first-page":"LBA588","DOI":"10.1200\/JCO.2024.42.3_suppl.LBA588","article-title":"[177Lu]Lu-DOTA-TATE in newly diagnosed patients with advanced grade 2 and grade 3, well-differentiated gastroenteropancreatic neuroendocrine tumors: primary analysis of the phase 3 randomized NETTER-2 study","volume":"42","author":"Simron","year":"2024","journal-title":"J Clin Oncol."},{"key":"2024100105350748000_65.10.1584.7","doi-asserted-by":"crossref","first-page":"e146","DOI":"10.1016\/S1470-2045(19)30821-6","article-title":"Radiotheranostics: a roadmap for future development","volume":"21","author":"Herrmann","year":"2020","journal-title":"Lancet Oncol."},{"key":"2024100105350748000_65.10.1584.8","unstructured":"Application number: 208700Orig1s000\u2014product quality review(s). U.S. FDA website. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2018\/208700Orig1s000ChemR.pdf. Published December 23, 2017. Accessed August 19, 2024."},{"key":"2024100105350748000_65.10.1584.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"2024100105350748000_65.10.1584.10","unstructured":"syngo.via: get the full picture. Siemens Healthineers website. https:\/\/www.siemens-healthineers.com\/en-us\/molecular-imaging\/pet-ct\/syngo-via. Accessed August 19, 2024."},{"key":"2024100105350748000_65.10.1584.11","doi-asserted-by":"crossref","unstructured":"Sasaki K Morioka D Conci S . The tumor burden score: a new \u201cmetro-ticket\u201d prognostic tool for colorectal liver metastases based on tumor size and number of tumors. Ann Surg. 2018;267:132\u2013141.","DOI":"10.1097\/SLA.0000000000002064"},{"key":"2024100105350748000_65.10.1584.12","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1002\/jso.24678","article-title":"The prognostic utility of the \u201ctumor burden score\u201d based on preoperative radiographic features of colorectal liver metastases","volume":"116","author":"Sasaki","year":"2017","journal-title":"J Surg Oncol."},{"key":"2024100105350748000_65.10.1584.13","doi-asserted-by":"crossref","first-page":"977111","DOI":"10.3389\/fonc.2022.977111","article-title":"Tumor burden score dictates prognosis of patients with combined hepatocellular cholangiocarcinoma undergoing hepatectomy","volume":"12","author":"Deng","year":"2023","journal-title":"Front Oncol."},{"key":"2024100105350748000_65.10.1584.14","doi-asserted-by":"crossref","first-page":"3196","DOI":"10.1111\/jgh.15593","article-title":"Tumor burden score as a new prognostic marker for patients with hepatocellular carcinoma undergoing transarterial chemoembolization","volume":"36","author":"Ho","year":"2021","journal-title":"J Gastroenterol Hepatol."},{"key":"2024100105350748000_65.10.1584.15","first-page":"1802\u20131811","article-title":"Nephrotoxicity after PRRT with 177Lu-DOTA-octreotate","volume":"43","author":"Bergsma","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2024100105350748000_65.10.1584.16","doi-asserted-by":"crossref","first-page":"505\u2013510","DOI":"10.1007\/s00259-013-2601-x","article-title":"Accurate assessment of long-term nephrotoxicity after peptide receptor radionuclide therapy with 177Lu-octreotate","volume":"41","author":"Sabet","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2024100105350748000_65.10.1584.17","doi-asserted-by":"crossref","first-page":"185","DOI":"10.3390\/nu15010185","article-title":"Long-term complications of radioligand therapy with lutetium-177 and yttrium-90 in patients with neuroendocrine neoplasms","volume":"15","author":"Saracyn","year":"2022","journal-title":"Nutrients."},{"key":"2024100105350748000_65.10.1584.18","doi-asserted-by":"crossref","first-page":"452\u2013458","DOI":"10.2967\/jnumed.117.189712","article-title":"Persistent hematologic dysfunction after peptide receptor radionuclide therapy with 177Lu-DOTATATE: incidence, course, and predicting factors in patients with gastroenteropancreatic neuroendocrine tumors","volume":"59","author":"Bergsma","year":"2018","journal-title":"J Nucl Med."},{"key":"2024100105350748000_65.10.1584.19","doi-asserted-by":"crossref","first-page":"100623","DOI":"10.1016\/j.adro.2020.11.008","article-title":"Lutetium Lu-177 dotatate flare reaction","volume":"6","author":"Salner","year":"2020","journal-title":"Adv Radiat Oncol."},{"key":"2024100105350748000_65.10.1584.20","first-page":"4074","article-title":"The implementation of Lutathera\u00ae therapy [abstract]","volume":"63","author":"Suison","year":"2022","journal-title":"J Nucl Med."},{"key":"2024100105350748000_65.10.1584.21","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12885-020-07710-7","article-title":"Lutetium oxodotreotide (177Lu-Dotatate) for the treatment of unresectable or metastatic progressive gastroenteropancreatic neuroendocrine tumors: a cost-effectiveness analysis for Scotland","volume":"21","author":"Smith-Palmer","year":"2021","journal-title":"BMC Cancer."},{"key":"2024100105350748000_65.10.1584.22","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1007\/s10198-021-01303-2","article-title":"Economic evaluation of orphan drug lutetium-octreotate vs. octreotide long-acting release for patients with an advanced midgut neuroendocrine tumour in the Netherlands","volume":"22","author":"Hagendijk","year":"2021","journal-title":"Eur J Health Econ."},{"key":"2024100105350748000_65.10.1584.23","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1016\/S1470-2045(21)00593-3","article-title":"Overall survival results from the NETTER-1 trial in neuroendocrine tumours: an important milestone","volume":"22","author":"Virgolini","year":"2021","journal-title":"Lancet Oncol."},{"key":"2024100105350748000_65.10.1584.24","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1007\/s00259-014-2735-5","article-title":"177Lu-Dota-octreotate radionuclide therapy of advanced gastrointestinal neuroendocrine tumors: results from a phase II study","volume":"41","author":"Paganelli","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2024100105350748000_65.10.1584.25","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.3390\/pharmaceutics13091463","article-title":"90Y\/177Lu-DOTATOC: from preclinical studies to application in humans","volume":"13","author":"Uccelli","year":"2021","journal-title":"Pharmaceutics."},{"key":"2024100105350748000_65.10.1584.26","doi-asserted-by":"crossref","first-page":"eadd9668","DOI":"10.1126\/sciadv.add9668","article-title":"Intertumoral lineage diversity and immunosuppressive transcriptional programs in well-differentiated gastroenteropancreatic neuroendocrine tumors","volume":"9","author":"Hoffman","year":"2023","journal-title":"Sci Adv."},{"key":"2024100105350748000_65.10.1584.27","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-17-0445"},{"key":"2024100105350748000_65.10.1584.28","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1007\/s13402-022-00727-z","article-title":"Novel preclinical gastroenteropancreatic neuroendocrine neoplasia models demonstrate the feasibility of mutation-based targeted therapy","volume":"45","author":"Viol","year":"2022","journal-title":"Cell Oncol (Dordr)."},{"key":"2024100105350748000_65.10.1584.29","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1007\/s00259-019-04439-9","article-title":"Prognostic significance of somatostatin receptor heterogeneity in progressive neuroendocrine tumor treated with Lu-177 DOTATOC or Lu-177 DOTATATE","volume":"47","author":"Graf","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2024100105350748000_65.10.1584.30","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s40644-023-00614-2","article-title":"Diagnostic accuracy of SSR-PET\/CT compared to histopathology in the identification of liver metastases from well-differentiated neuroendocrine tumors","volume":"23","author":"Fabritius","year":"2023","journal-title":"Cancer Imaging."},{"key":"2024100105350748000_65.10.1584.31","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s40658-024-00620-8","article-title":"Prediction of [177Lu]Lu-DOTA-TATE therapy response using the absorbed dose estimated from [177Lu]Lu-DOTA-TATE SPECT\/CT in patients with metastatic neuroendocrine tumour","volume":"11","author":"Ha","year":"2024","journal-title":"EJNMMI Phys."},{"key":"2024100105350748000_65.10.1584.32","doi-asserted-by":"crossref","first-page":"2997","DOI":"10.1007\/s00259-023-06257-6","article-title":"The relationship between tumour dosimetry, response, and overall survival in patients with unresectable neuroendocrine neoplasms (NEN) treated with 177Lu DOTATATE (LuTate)","volume":"50","author":"Alipour","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2024100105350748000_65.10.1584.33","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.123.265987"},{"key":"2024100105350748000_65.10.1584.34","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.123.266614"}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.124.267964","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T12:35:36Z","timestamp":1727786136000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.124.267964"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,12]]},"references-count":34,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2024,10,1]]},"published-print":{"date-parts":[[2024,10]]}},"alternative-id":["10.2967\/jnumed.124.267964"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.124.267964","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,12]]}}}